Positron emission tomography in gynecological malignancies

Rakesh Kumar, Anil Chauhan, Suman Jana, Simin Dadparvar

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Positron emission tomography (PET) is a functional diagnostic imaging technique. F-18 fluoro-2-deoxy-D-glucose (FDG) is a commonly used radiopharmaceutical that is an analog of glucose. PET with FDG is now the standard of care in initial staging, monitoring the response to the therapy and management of various cancers. There is not sufficient data to support the use of PET in the initial diagnosis of cervical cancer; however, FDG-PET has a role in initial staging in the detection of distant metastases in patients with cervical cancer. PET has limited value in lesion localization in early stages of ovarian cancer, but plays a significant role in identifying recurrent tumors in patients with rising tumor markers. In this article, the clinical application of PET in gynecological malignancies is reviewed.

Original languageEnglish (US)
Pages (from-to)1033-1044
Number of pages12
JournalExpert Review of Anticancer Therapy
Issue number7
StatePublished - Jul 2006
Externally publishedYes


  • Cervical cancer
  • Endometrial cancer
  • Fluorodeoxyglucose
  • Oncology
  • Ovarian cancer
  • Positron emission tomography


Dive into the research topics of 'Positron emission tomography in gynecological malignancies'. Together they form a unique fingerprint.

Cite this